Loading organizations...

NovaSignal is a technology company.
NeuraSignal, formerly NovaSignal, develops the NovaGuide Intelligent Ultrasound System. This platform integrates Transcranial Doppler (TCD) technology with automated robotics and AI, autonomously acquiring ultrasound data. Providing critical cerebral blood flow insights, it is the first and only FDA-cleared, fully automated cerebral ultrasound for rapid, non-invasive diagnostic and surgical support.
The company originated in 2013 as NovaSignal, inspired by co-founder Robert Hamilton’s research in Malawi. His use of transcranial doppler ultrasound highlighted a profound need for accessible medical data. This insight drove the mission to democratize crucial brain health, leveraging his engineering and medical background.
Healthcare professionals utilize the NeuraSignal platform to swiftly detect and manage complications, improving patient outcomes. The system minimizes invasive procedures, enhancing cost efficiency and clinical operations. NeuraSignal’s vision is to unlock comprehensive blood flow data, broadening access to vital medical insights and empowering clinicians for patient care.
NovaSignal has raised $104.0M across 6 funding rounds.
NovaSignal has raised $104.0M in total across 6 funding rounds.
NovaSignal has raised $104.0M in total across 6 funding rounds.
NovaSignal's investors include Alpha Edison, Ted Koutouzis MD, Josh Porter, JSR Limited, Taiyu Capital.
NovaSignal Corp. is a medical technology company that develops the FDA-cleared NovaGuide™ Intelligent Ultrasound, combining non-invasive ultrasound, robotics, and artificial intelligence to assess real-time cerebral blood flow.[1][2] It serves physicians in neurocritical care, supporting clinical decision-making via cloud computing and data analytics to improve patient outcomes, with a mission to save lives by unlocking the hidden power of blood flow data.[1][2] The company, now operating under NeuraSignal following a 2023 acquisition, targets challenges in transcranial Doppler (TCD) ultrasound for conditions like stroke and cerebral vascular issues, headquartered in Los Angeles with 79 employees.[1][3]
NovaSignal was founded in 2013 by Dr. Robert Hamilton, who developed the core technology during his Ph.D. in Neurosurgery at UCLA, drawing from hands-on experience in neurocritical care and research in resource-limited settings like Haiti, China, and Malawi.[3][6] There, Hamilton identified the need for automated, accessible TCD ultrasound to study pediatric malaria and sickle cell anemia, inspiring the company's focus on robotics and AI to overcome manual ultrasound limitations.[3] He partnered with MBA students Dan Hanchey and Leo Petrossian, leading to early innovation in cerebral blood flow monitoring; in 2023, NeuraSignal acquired NovaSignal's business, continuing its legacy while expanding global impact, such as donating Lucid™ TCD systems to Nationwide Children’s Hospital for African research centers.[3]
NovaSignal rides the wave of AI-driven medtech innovation, particularly in neurology where real-time cerebral blood flow data is vital for stroke, trauma, and vascular diseases amid rising global incidences.[1][2][3] Timing aligns with post-pandemic emphasis on remote diagnostics and automation, fueled by advances in robotics and cloud AI that address clinician shortages and manual ultrasound inconsistencies.[3][4] Market forces like aging populations and health equity demands favor its non-invasive approach, influencing the ecosystem by setting standards for automated TCD and enabling research in global health disparities, as seen in sub-Saharan Africa initiatives.[3]
NeuraSignal (post-NovaSignal acquisition) is poised to expand NovaGuide™ adoption in hospitals worldwide, leveraging AI enhancements for predictive analytics in stroke care and beyond.[3] Trends like edge AI in wearables and tele-neurology will amplify its reach, potentially partnering with major health systems for integrated platforms. Its influence may evolve from niche innovator to ecosystem leader in cerebral monitoring, driving better outcomes in underserved areas while scaling commercially—unlocking blood flow data's power to truly transform lives.[1][3]
NovaSignal has raised $104.0M across 6 funding rounds. Most recently, it raised $37.0M Series C in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $37.0M Series C | Alpha Edison, Ted Koutouzis MD | Josh Porter |
| May 1, 2019 | $22.0M Series C | Alpha Edison | Josh Porter |
| Jan 1, 2018 | $15.0M Series B | Alpha Edison | Josh Porter |
| Apr 10, 2017 | $10.0M Other Equity | Ted Koutouzis MD | |
| Apr 1, 2017 | $10.0M Venture Round | Alpha Edison | |
| Dec 21, 2015 | $10.0M Series A | JSR Limited, Taiyu Capital |